Friday, November 20, 2026

United Health Care Undergoes Audit of its Medical Policy Development Process

United Healthcare has released a detailed report - by FTI and Rubrum Consulting - on how its medical policies and evidence reviews stack up.  

## ##

UnitedHealthcare Opens Its Medical Policy Process to Independent Review

A review of how coverage policies are made

UnitedHealth Group has released an independent review of UnitedHealthcare’s medical policy development process. Commissioned by the company and conducted by FTI Consulting and Rubrum Advising, the review examined how its medical policy team develops, approves, maintains, and revisits policies. UnitedHealth Group announced the findings on November 12, 2026. UnitedHealth Group

The reviewers assessed the team’s procedures against external standards and examined nine selected policies, spanning subjects from molecular testing for blood cancers to sleep apnea and cardiac monitoring. They described the development process as strong and evidence based. The team includes more than 80 staff members, and policies are reviewed at least annually. The nine sampled policies met the review’s criteria.

We present the findings as written.  Readers of the reports should be aware of the chance that self-commissioned reports might skew favorable.

When appeals point back to the policy

One finding deserves attention beyond UnitedHealthcare. According to the full report, the medical policy team receives a monthly report on appeals and overturned decisions. It looks for patterns that may reflect a problem with a policy’s wording, its interpretation by reviewers, or a change in clinical evidence.

Those possibilities call for different responses. A sound coverage criterion may be stated so densely that clinicians struggle to follow it or reviewers apply it inconsistently; clearer language or education may resolve the problem. In another case, an appeal may expose new medical evidence that warrants reconsidering the criterion itself. The reviewers singled out this use of appeals data as a strength of UnitedHealthcare’s process.

Strong process, difficult documents

Thursday, November 19, 2026

FDA Publishes Regulatory Approach to AI for Cytology

Participants to the May 2026 AMA CPT in Boston may recall that Hologic proposed a code for AI Cytology, but the AMA CPT committee rejected it because there was already a decades-old code for computer-assisted cytology, after which they turned back to painting bison on the walls with chalk.

FDA is moving forward, and has just published final paperwork for AI-assisted cervical cytology.  91 FR 69687.    Find it here.   Find an interesting Linked In article by Michelle Lott here.

The story goes back five years to 2021.  On August 27, 2021, FDA received Hologic Inc.’s request for De Novo classification of the Genius Digital Diagnostics System with the Genius Cervical AI algorithm.  FDA is codifying the classification of the device by adding 21 CFR 864.3900.  The device, FDA finalized in 2024 as DEN210035.   

USPSTF - It's Baaaack! From GAO to Agenda...

 

USPSTF Back in Business After 20 Months; 
AHRQ Director Envisions AI-Driven Evidence Reviews;
GAO Finds AHRQ Funding Impoundment Illegal

 

Chat GPT 6, November 20, 2026 (Los Angeles).  Exclusive to: Discoveries in Health Policy.

After an extraordinary 20-month hiatus, the U.S. Preventive Services Task Force (USPSTF) reconvened on November 19–20, 2026. The meeting is noteworthy not only for the resumption of the panel's activities, but also for a new transparency initiative, an ambitious vision for artificial intelligence in evidence-based medicine, and the backdrop of a recent Government Accountability Office (GAO) decision concerning the dismantling of research infrastructure at AHRQ.

The USPSTF last held a regular meeting in March 2025. In September 2026, HHS Secretary Robert F. Kennedy Jr. appointed eight new members to the 16-member task force.



A Full Agenda, Including Three Cancer Screening Topics

The November 19–20 meeting has a substantial agenda of interest to the diagnostics community. Topics include:

Wednesday, November 18, 2026

Will Analogies Speed You Through Regulators? Through Coverage?

Using health technology as an example, a new article in Harvard Business Review gives data-based tips on how to succeed with regulators - and some may apply to payers as well.

The original article is Pahnke et al. in Strategic Management Journal:  Strategic positioning and accelerating regulatoryclearance for new ventures, here.   It's covered and summarized in Harvard Business Review by Blanding (11/18/2026) here.  I got both open access without registration today.

###

AI CORNER

###

A new study of 239 medical device startups finds that their choice of FDA predicates is associated with the speed of 510(k) clearance. For a first device, a focused comparison to a familiar product in the same category appears helpful; for a second, the firm’s own cleared device may be the strongest reference. The findings illuminate how human categorization operates inside regulatory review, but multiple predicates may also signal a genuinely complex product. We consider what this research suggests for MolDX—and why a clear analogy alone cannot produce payer coverage.

_____

How to Make a New Product Legible to a Gatekeeper

A business-school study of FDA predicates, human cognition, and the harder analogy to diagnostic coverage

The first thing a company says about a novel product is often a comparison. It is “like” an established product, except for the feature that makes it worth buying. Such analogies help an investor decide what market to imagine. They can also help a regulator decide what work lies ahead. But these audiences have different jobs, and the same analogy need not work equally well for both.

In a new Strategic Management Journal paper, Emily Cox Pahnke, Tiona Zuzul, and Michael Howard ask a surprisingly concrete question: When a medical-device startup identifies earlier devices in its FDA 510(k) submission, does its choice of comparisons affect how long clearance takes? Their answer is yes, with a striking change between a firm’s first and second products. A shorter HBS Working Knowledge article presents the managerial version: make the comparison easy for a busy reviewer, and build a product sequence that can use its own earlier clearance. The underlying research article is more qualified than a slogan about “use one predicate.” sms.onlinelibrary.wiley.com



What exactly did Pahnke and colleagues study?

AMA CPT for February 4-6, Lab Codes Posted for Early Comment

 AMA CPT hasn't yet posted registration for the February 2027 Los Angeles AMA CPT.

https://www.ama-assn.org/membership/events/cpt-editorial-panel-meeting

But they've posted the lab applications, which go through early comment due ot their special subcommittees.

Lab codes are here:

https://www.ama-assn.org/system/files/february-2027-lab-agenda.pdf

Requests to review and comment - see the blue Link in the PDF above.

Comment requsts opened Nov 13 and comments must be In (via a portal) by December 4.

Category 1 applications

ApoE (Alzheimer), CYP 2B6, NAT2, and an MS MAAA, assay for Dexamethasone

Category III

Move 6 Cat III codes to a new, dedicated subcategory

Revise a bladder algorithm code

Tumor microenvironment biomarkers.

Algorithm in WSI for CRC prognosis

Breast malignancy via nanobiomechanical measures

Capillary self colection device




Trop2 as Oncology Companion Diagnostic: Pivotal Paper from Garassino et al.

 We've been hearing for a couple years that important new antibody-payload drugs will need IHC diagnostics, rather than the genomic ones we're used to (KRAS, etc).

Now we have a pivotal paper about the diagnostic TROP2 for datroway / datopotamab deruxtecan.  See Garassino et al, Nature Medicine, November 11, 2027.

Key CDx point:  They tried regular scoring 1+ 2+ 3+, and it didn't work.  They used elaborate software applications...and it did.

Here's a Chat GPT 6 summary.

Computer can read this symbol, Pathologist can't...


# # #

TROP2’s New Companion Diagnostic Measures
Where the Protein Is

November 18, 2026

TROP2 has been a frustrating biomarker for TROP2-directed drugs. About 90% of non-small-cell lung cancers express the protein, yet conventional immunohistochemistry has done little to identify which patients benefit from datopotamab deruxtecan (Dato-DXd, marketed as Datroway). 

  • A new Nature Medicine paper reports a more useful question for the pathologist’s slide: How is TROP2 distributed between the tumor cell membrane and its cytoplasm?
    • Garassino et al., 2026

That question requires sophisticated image analysis. AstraZeneca developed a proprietary computational pathology platform called quantitative continuous scoring (QCS).  Roche is developing the accompanying VENTANA TROP2 companion diagnostic, which combines an immunohistochemistry assay, slide scanning, digital pathology software, and an algorithm incorporating QCS. The resulting measure is the normalized membrane ratio, or NMR. 

Roche received FDA Breakthrough Device Designation for the system in 2025; the designation is not FDA approval. diagnostics.roche.com

AMA November 20: Town Hall on Defining "Widespread Use"

 One of the trickiest gates between you and a new AMA CPT code is "widespread use."  AMA deliberately doesn't define it, because 400 cases per year of 1000 possible is "widespread" use, but 4000 cases per year of 1M possible may not be "widespread" use.   

(Also, AMA prefers to gate new codes to services in widespread use to allow an immediate and large enough RUC valuation survey.)

'Widespread use" is a frequent cause of CPT denials, because other criteria are more objective (such FDA approval yes-no, effectiveness shown in publications  yes-no, a new and distinct service yes-no.)

Here's the web page for the November 20 event on defining Widespread Use.  3 central (4 eastern, 1 pacific).

https://www.ama-assn.org/membership/events/cpt-editorial-panel-widespread-use-criteria-town-hall

###

Here's a step by step....

###

AMA CPT – Keeping Up with Reimbursement Events

Tuesday, November 17, 2026

Geneoscopy, Exact Sciences: All Patent Claims Settled ("Obviousness")

On November 17, 2026, a press release from Geneoscopy announces the settlement of claims and counterclaims between the two companies.

Pivotal steps along the legal pathway were PTO rulings that two major Exact patents, '746 and '781, failed a judicial review for "obviousness."   Obviously, the same patents had passed their patent reviews.  What changed?  What was most important, when they came to the courtroom for litigation?

We found key court documents and uploaded to Chat GPT 6 for discussion.

The patents remind us that, just the basic business of preserving nucleic acids during shipping, in the stool biospecimen, is a big hurdle and not to be taken lightly.   

###

I am not an attorney, nor is Chat GPT.  For the chance to read an AI report on this topic, Chat GPT writes...

###

Geneoscopy and Exact Sciences Settle:
A Closer Look at Patent “Obviousness”

On November 17, 2026, GenomeWeb reported that Geneoscopy and Exact Sciences had settled all pending litigation between them in federal district court. The dispute involved their competing stool-based colorectal cancer screening products, ColoSense and Cologuard. According to Geneoscopy’s announcement, the settlement includes no admission of liability or wrongdoing, and its other terms remain confidential.

Monday, November 16, 2026

CMS RELEASES "CRUSH" ANTI FRAUD RULE: ZIPPO RE LABS

CMS has released a proposed version of its new anti fraud CRUSH rules.  While the roll-out seemed to be "half DME and half lab industry," the proposed rule hardly mentions the word "laboratory."

Press:

https://www.cms.gov/newsroom/press-releases/cms-crush-proposed-rule-aims-reap-nearly-90-billion-taxpayers-savings-targeting-fraud-across

FAQ:

https://www.cms.gov/newsroom/fact-sheets/comprehensive-regulations-uncover-suspicious-healthcare-crush-proposed-rule-cms-6098-p

Proposal:

https://public-inspection.federalregister.gov/2026-23461.pdf


CMS Releases CRUSH: 545 Pages on Fraud, and Labs Barely Appear

[AI Claude]

On November 16, 2026, CMS released the Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) proposed rule, CMS-6098-P. The agency says it would save nearly $90 billion over ten years across Medicare, Medicaid/CHIP and the ACA Marketplace. It is a standalone, discretionary program integrity rule rather than an annual payment rule. CMS says it intends to issue a rule like this every year from now on. The Federal Register publishes it November 19, and comments are due January 19, 2027.

The press release goes heavily after DME, hospice and Marketplace brokers. Administrator Oz's quote mentions fake canes and wheelchairs, healthy seniors enrolled in hospice, and consumers signed up for Marketplace plans without their consent. The largest single dollar item is Medicare Advantage RADV reform. CMS would codify no fee-for-service adjuster and extrapolation starting with payment year 2018 audits, which it estimates at about $9 billion per payment year. Other items include mandatory fraud reporting by MA and Part D plans, a new Medicaid audit structure for eligibility, a 60-day overpayment rule for Medicaid fee-for-service, and tighter rules for Marketplace agents and brokers.

Where are the labs?

Much of the recent fraud debate in diagnostics has been about laboratory billing. Readers in that sector might have expected a large lab section. There isn't one. Explicit references to laboratories are sparse and largely incidental. The word "laboratory," for example, appears 3 times.

  • once in a Medicaid list of "disclosing entities" (p. 213)
  • once in a regulatory subject index
  • once as a reassurance that a medical building housing "two laboratories" next to other practices is not, in itself, a sign of fraud (p. 199)

Genetic testing comes up only once. It appears in a DOJ case summary in the DMEPOS section (p. 184): a Texas defendant sentenced in March 2026 for a $61.5 million scheme. An offshore call center sold Medicare beneficiaries braces, foot baths and genetic tests they did not need. There is no lab provision, no CLIA hook, and nothing about MolDX, PLA codes or test-specific edits.

  • The rule does contain several broad enrollment changes that apply to every provider and supplier type, including independent labs.
  • For lab compliance teams, those are the parts to read.

CMS Publishes Template for Uses of SUPER INTELLIGENCE in Medicare, Medicaid

Recall that recently, HHS ordered that HHS, CMS, NIH, FDA, all use "SUPER INTELLIGENCE" rather than artificial intelligence.  My blog.

We've now got a brand new 8 page report on how cMS wants to use SUPER INTELLIGENCE to lower costs while giving better answers and faster care.  And it's getting some press.

Find the 8 page white paper here:

https://www.cms.gov/files/document/clinical-si-roadmap.pdf

Coverage at Becker Health IT here.  At Orange Slices here.

##
AI CORNER

##


CMS’s AI Roadmap: Better Diagnostics, More Physician Capacity—and Lower Costs

CMS has released an eight-page Clinical Super Intelligence Roadmap, laying out an ambitious federal agenda for clinical AI. For readers in radiology, pathology, and genomics, it deserves attention for both its enthusiasm about technology and its pointed message about reimbursement: CMS wants AI to improve care while bringing costs down.

Read the CMS announcement and the eight-page roadmap. The document was posted November 13.

The roadmap’s subtitle is Better Answers, Faster Care, and Lower Costs. Those objectives could apply directly to software that helps a radiologist complete an interpretation, a pathologist sign out a case, or an oncologist understand a complex molecular report. Much of the immediate policy discussion concerns primary care and chronic disease, but the implications for diagnostic medicine are substantial.

The payment message deserves particular attention. On page 7, CMS states:

“Technology should be deflationary to costs.”

FDA Downclassifies Again: IHC for CDx

Update: See also Kelly Gordon's Linked In article here.

# # #

I posted a blog on September 3, 2026, that FDA had recently downclassified oncology cDx with ISH or FISH from  Class III (PMA) to Class II (e.g. 510k or de novo 510k).  At the time, the news was two weeks old but had gotten very little press.

Now, in November, similar news for a much larger area, CDx with IHC, immunohistochemistry.

This should be the auto AI that Google itself gives you: 

https://share.google/aimode/O5TrMaWcf2m8Ki6J1

Here's the FDA reclassification proposal:

https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with

FDA accepts public comment now and will finalize in a year or two.  You have until January 11, 2027.


Fun fact: Pubmed tells us FDA wrote about the topic on June 3, 1998, PMID 10179865.   Here.  63fR30132.

Read about the new publication at Sharon Liang at linked in here.  And Kelly Gordon here.

IHC is hardly cut and dried, see debates about PDL1 staining and about Enhertu in pan cancer here.

###

AI CORNER

###


FDA Proposes Easier Market Entry for Oncology IHC—and a Regulatory Gem from 1998

The proposed move from PMA to 510(k) has a revealing historical precedent.

The 2026 Proposal

On November 12, FDA proposed reclassifying oncology immunohistochemistry (IHC) test systems from Class III to Class II, replacing premarket approval (PMA) with 510(k) clearance and special controls. Comments are due January 11, 2027.

The scope includes companion diagnostics essential to treatment selection, plus certain tests that inform a drug’s benefits or risks without being prerequisites for treatment. FDA proposes a new regulation, 21 CFR 864.1895.

Substantial Evidence Requirements Remain

The proposed controls require analytical and clinical performance evidence, validated scoring thresholds, and reproducibility—including between readers and near clinical decision cutoffs.

Former FDA leader Sharon Liang, in her recent LinkedIn commentary, highlights why this matters for PD-L1: different antibody clones, scoring systems, thresholds, and reader variability complicate reliable treatment selection. Her discussion places IHC within FDA’s broader effort to reclassify higher-risk IVDs.

Using AI at my Desk at Work: A Weekly Agentic Search for AI Report Generation Advances (Radiology or Pathology)

Each Monday, I used "agentic AI" to run a complex scheduled AI search in Chat GPT.  The topic is new publications related to generating either Radiology or Pathology reports by AI, including news about FDA reviews, etc.  (It also tracks the FDA K260303 web page).

##

Here is a cut/paste out of what it delivered to me for November 16, 2026.  Note that at bottom, I also gave it a link to news from Cognita, which it then discusses.

##

Weekly AI Diagnostic Report-Generation Watch

Monday, November 16, 2026

Bruce,

The most consequential new finding is from AMP 2026: University of Michigan investigators presented an AI system that generates evidence-supported molecular pathology reports, while Memorial Sloan Kettering researchers demonstrated AI-assisted selection of molecular tests. Together, these developments approach the integrated laboratory workflow we've been tracking.

Thursday, November 12, 2026

Two Authors, Two Books on Digital Pathology

 This week, I ran across two authors on Linked In who have each written a book that introduces the world of digital pathology.

The first author is Dr. Aleks Zuraw.  Her book is a take-home associated with a webinar she is giving this week.   "Digital Pathology 101, 2nd Edition."  Find registration here:

https://lnkd.in/p/grdGQian

and

https://lnkd.in/p/gVByAMuS

####

The second author is Dr. Luis Cano.  His book is a highlighted link on his Linked In homepage  find it here:

https://payhip.com/b/wldfe 

####

Chat GPT 6 reviews both books together.

####

I recently discovered two authors on LinkedIn whose introductory books offer complementary perspectives on digital pathology: Luis Cano’s Getting Started with Digital Pathology and Aleksandra Zuraw’s Digital Pathology 101, now in its second edition. Both help readers understand how scanned tissue images can support diagnosis, research, and computational analysis, but their emphasis differs substantially.

Cano’s concise guide is particularly effective at introducing quantitative tissue analysis, including cell counting, biomarker scoring, segmentation, and spatial relationships within tumors. His practical advice encourages newcomers to begin with accessible software, public datasets, and manageable projects.

Zuraw provides a broader introduction to the infrastructure and organizational work required for implementation. Her strongest sections address validation, workflow integration, ongoing performance monitoring, and the distance between developing an algorithm and deploying it reliably. Her veterinary and pharmaceutical background also supports distinctive coverage of toxicologic pathology and regulated drug development.

Neither book provides a complete treatment of clinical utility, reimbursement, procurement, or investment analysis. Nevertheless, both are valuable starting points. 

Pathologists, translational researchers, and industry professionals who must connect scientific possibilities with practical adoption should consider reading both: Cano for an accessible entry into image analysis, followed by Zuraw for a deeper understanding of implementation and operational responsibilities.

FIND FULL REVIEW:

https://drive.google.com/file/d/1Wisq0R2DxSGfh3o1--_7nCj3YBht3T4q/view?usp=sharing 





Brief Blog: How CMS Updates Products Covered Under NCDs

A brief update on how CMS covers products that are covered by definition, under an NCD.  

The example here is NCD 90.2, Uses of NGS in Cancer.   FDA cleared-or-approved companion diagnostics are covered by this NCD for on-label uses.   Often, this means PMA CDx approval for one or more indications (gene-drug), and a secondary FDA label which is for profiling mutations in tumor genes in solid tumors, for the use of the physician via guidelines.

So on October 23, 2026, CMS released CR 14653, T 14022, Revisions to NCDs.  It's released on October 23, effective April 1 2027 (the new quarter) ("unless otherwise stated"), implementation date April 5, 2027.

https://www.cms.gov/files/document/r14022otn.pdf

On page 3 we read that per task order 14653.1, the PGDX Elio Tissue Complete CDx is covered effective back on the FDA approval date July 30, 2026.  Use CPT 81459 until a PLA is established.  

The last page of the CR includes a link to a cloud zip file for Excel version.


Labcorp web page, 505 total genes and signatues TMB, MSI.

https://www.labcorp.com/oncology/providers/testing-solutions/kitted-solutions/pgdx-elio-tissue-complete-cdx

Product brochure 4pp

https://www.labcorp.com/content/dam/labcorp/files/oncology-launch/etc-cdx-oncology-brochure-2026.pdf


###

I believe that a version of PGDx elio had FDA 510k clearance (not approval) for tumor profiling, whereas this FDA revision is a PMA for a BRAF gene in melanoma PLUS tumor profiling use.  Here, here.

###

It's clear to me that program instructions defined effective date as the coverage date, and implementation date as the LATEST or LAST date to "implement" that coverage.

https://www.discoveriesinhealthpolicy.com/2026/02/this-may-save-your-reimbursement-nerd.html

However, MACs may say CMS forbids them to cover for that effective date and later, UNTIL the "implementation date" has passed.

###

81459 pays $2989 (no PAMA change) and represents,

Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; dna analysis or combined dna and rna analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


Wednesday, November 11, 2026

PAMA: The Secret Data Views that CMS Never Displays (for GSP Genomic Sequencing Procedures)

Medicare genomic sequencing pricing under PAMA is based on anywhere from 200 to 275,000 claims for the "GSP" service type.   For Exome and Genome, a large body of claims were paid at about half the Medicare CLFS rate.

Note that none of this data is Medicare data; it's private payer data...the behavior of private payers

###

Goodbye to a myth?

Are CMS CLFS prices a benchmark that strongly drive the market?   Well, the data shows that for some  codes (from 81408 to 81425) the actual market prices can be skewed or centered quite a distance from the CLFS benchmark at the time.

###

What's Up?

Medicare's public raw data files for PAMA 2026 provide interesting data views.  Here, I reveal some more, using simple commands and Chat GPT 6.

Case Study: GeneDx (ticker WGS)

The information is relevant. Over the past year, GeneDx has been battling reimbursement issues, with share price varying in that time from around $33 to around $170.  On one day in May, the share price dropped 50%.   

PAMA Prices Trend Down for Exome, Genome

Not helping is the downward trend in the latest PAMA data for genomic procedures, including 81415 exome and 81425 genome.   Here's some data; I include the $2000 (CLFS) rare gene code 81408.

In each case below, the current CMS CLFS price is in the fourth column.  But a lot of the reported payments are cheaper: most of the claims for 81415 (exome, middle row) and 81425 (genome, bottom row) are in the second and third columns.  Those are claims at $1400-2800 [second column] and $2800-4200 [third column.] 

Note that exome, but not genome, has a significant bump to-the-right (blue bar in column 6).  We showed earlier that such behavior, high-paying plans, can really drive free cash flow and profit.  


Star - CLFS price

The skew to the left is even more prominent for 81408, where many payments populate the far left bar ($0-550, while CMS price, $2000).

So if my market depended on the price of Genome being $5000 or nearby, and the largest bucket was column 2, $1400-2800... eeek.

##

Also in the 814nn series, GSP or Genomic Sequencing Procedures, CMS let us count how many services or claims were reported for about 36 GSP codes.   Here is a sample screen shot:


Here's the full table:


Here's the Tier 2 claims, 81400 to 81408 as a bar chart.